Pyxis Oncology
PYXS
72 hedge funds and large institutions have $97.8M invested in Pyxis Oncology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 9 closing their positions.
517% more capital invested
Capital invested by funds: $15.8M → $97.8M (+$81.9M)
340% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 5
244% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 9
167% more call options, than puts
Call options by funds: $543K | Put options by funds: $203K
41% more funds holding
Funds holding: 51 → 72 (+21)
19.63% more ownership
Funds ownership: 19.85% → 39.48% (+20%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$17.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.9M |
| 3 |
SC
Stempoint Capital
New York
|
+$7.55M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$6.99M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$2.9M |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$909K |
| 2 |
VPC
Vestal Point Capital
New York
|
-$792K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$432K |
| 4 |
Two Sigma Advisers
New York
|
-$204K |
| 5 |
HIS
Harvest Investment Services
Oakbrook Terrace,
Illinois
|
-$201K |
PYXS Hedge Fund Activity: Q1 2024 in Review
72 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2024, worth a combined $97.8M — up 517% from $15.8M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PYXS positions and 9 closed out — a net gain of 22 holders — while 22 added to existing stakes and 5 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $17.6M. The largest seller was Renaissance Technologies, cutting an estimated $909K.
- 72 institutional investors held Pyxis Oncology (PYXS) as of Q1 2024, up from 51 in Q4 2023.
- Funds reported $97.8M of Pyxis Oncology stock for Q1 2024, up 517% quarter-over-quarter.
- 31 funds opened new Pyxis Oncology positions in Q1 2024 and 9 closed out, a net change of +22 holders.
- The largest Pyxis Oncology buyer in Q1 2024 was Deep Track Capital, an estimated $17.6M added.
- The largest Pyxis Oncology seller in Q1 2024 was Renaissance Technologies, an estimated $909K sold.
Based on aggregated 13F filings for Q1 2024.